About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- 218 adults with genetically confirmed primary mitochondrial myopathy
- Sample size
- 218
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
The trial's primary endpoints were not met, so it does not support a benefit in this population. Funder not checked. Abstract read via Europe PMC; full text not read.
Cited in
Phase 3 in mitochondrial myopathy, not met
Elamipretide · Research finding
MMPOWER-3 tolerability
Elamipretide · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.